Citations

Clear

16281 citation(s) found for "Yu, David".

Abstract 5638: Autologous CD34+ Cell Therapy for Refractory Angina: 12 Month Results of the Phase II ACT34-CMI Study
Henry, Tim, Schatz, Richard A. , Lee, Joon Sup, Bass, Theodore A., Schaer, Gary L. , Niederman, Alan, Mendelsohn, Farrell O., Davidson, Charles J. , Waksman, Ron , Soukas, Peter , Simon, Daniel I. , Chronos, Nicolas, Fortuin, F. David , Wong, S. Chiu, Taussig, Andrew, Rava, Amish N, Sherman, Warren, Kereiakes, Dean J. , Strumpf, Robert K., Port, Steven, Pieper, Karen S. , Adams, Peter X., Harrington, Robert A. , Losordo, Douglas W. , Costa, Marco Antonio , Davidson, Charles J. , Huang, Paul P. , Weintraub, Neal L. , Yeung, Alan C. , Rosenfield, Kenneth , Port, Steven C.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 120 | Issue: suppl_18 | Pages: No page available

10.1161/circ.120.suppl_18.s1132-a Get It

Background: Refractory angina(Ang) effects 150 –250,000 pts in the US alone. These individuals have exhausted options for revasc and continue to have lifestyle limiting ang despite optimal medical Rx. Pre-clinical studies provided evidence that human CD34+ cells(CD34) can stimulate new blood vessel formation in ischemic myocardium(Myo), improving perfusion and function. We performed a phase 2 study of intraMyo injection of autologous CD34 in pts with CCS Class 3 and 4 Ang to obtain evidence for feasibility, safety and bioactivity. Methods: A phase 2 randomized, double-blind, placebo-controlled clinical trial was performed at 26 centers in the United States. There were 3 treatment groups: placebo, low dose (1×10^5 CD34/kg body wt) and high dose (5×10^5 CD34/kg). All pts underwent mobilization with GCSF 5 mcg/kg/day SC for 5 d, followed by apheresis on d5 to collect mononuclear cells. On day 6 CD34 were purified from the collected cells using the Isolex 300i device. After lot release testing, CD34 were injected endocardially at 10 locations in the ischemic Myo using the Myostar catheter following NOGA mapping. Placebo injections consisted of identical volumes of the diluent only. Results: A total of 167 pts were randomized and completed the injection procedure and 162 completed the 6 mo evaluation. The mean age of subjects was 61.0±8.9, there were 22 female and 145 male subjects. Trop was elevated in 26 pts at baseline and in 71 at some point following GCSF or injection. At 6 mo CD34 treated pts showed more reduction in ang frequency (−8.6 placebo vs 14.2 low dose) and improved ETT time (+69 sec placebo vs. +138 low dose). At 12m CD34 treated continue to show more reduction in angina (−8.2 placebo vs. −15.0 low dose) and improved ETT (+58 sec placebo vs. + 139 sec low dose). For key endpoints the high dose group results were inferior to low dose. The 12m data set has been locked and is being analyzed and the results of the completed analysis will be presented. Conclusions: Autologous CD34 cell therapy was associated with improved exercise tolerance and reduced angina in no-option pts with intractable angina. Ongoing analysis will determine endpoints, sample size and suitability of this therapy for a phase III study in no-option pts with refractory angina.
2006 Helen B. Taussig Memorial Lecture—Plato, Epistemology, and Cardiology, or, Should Doctors Think Like Lawyers?
Driscoll, David O

Mayo Clinic

Circulation | April 23, 2024 | Volume: 114 | Issue: suppl_18 | Pages: No page available

10.1161/circ.114.suppl_18.ii_e-a Get It

Mistakes occur because doctors make diagnoses and therapeutic decisions on the basis of what they think is correct knowledge but is, in fact, incorrect knowledge. Attainment of knowledge relies on sense experience, and sense experience can be misleading. Medical tests are interfaces between patients and doctors, and sense experiences are distorted by these interfaces. Knowledge can be attained by “reasoning.” Deductive reasoning, utilizing a properly constructed syllogism, is the only way one attains knowledge with 100% certainty. Knowledge attained by all other methods is only correct with a probability <100%. In addition to reasoning, one can gain knowledge on the basis of appeals to authority (eg, expert witness), experience, intuition, revelation, and faith. The level of certainty of knowledge that one can achieve is related to the method used to achieve that knowledge; deductive reasoning is more reliable, for example, than intuition, revelation, or faith. Doctors and lawyers must determine what is true or correct about matters that are uncertain or contingent. Doctors, like lawyers, deal with evidence (medical history and test results). To avoid errors, doctors must treat evidence with the same level of skepticism that lawyers do. Doctors must be aware of what constitutes quality of evidence. If they are not, medical errors will result. In summary, doctors must understand the basic principles of epistemology. Doctors never deal with 100% certain knowledge and hence must rely upon “wisdom,” which is the ability to make the right decision in the absence of certain knowledge.
Non‐alcoholic fatty liver modifies associations of body mass index and waist circumference with cardiometabolic risk: The CARDIA study
Mathew, Mahesh, Pope, Zachary , Schreiner, Pamela J. , Jacobs, David R. , VanWagner, Lisa B. , Pereira, Mark A. , Pope, Zachary C, Pereira, Mark A , Terry, James G , VanWagner, Lisa B , Jacobs, David R , Terry, James G.

Mayo Clinic

Obesity Science & Practice | April 23, 2024 | Volume: 10 | Issue: 2 | Pages: No page available

10.1002/osp4.751 | PMID 38655127 Get It

Abstract Background Non‐alcoholic fatty liver disease (NAFLD) is recognized as a prevalent determinant of cardiometabolic diseases. The association between NAFLD and obesity warrants further research on how NAFLD modifies associations between body mass index (BMI) and Waist circumference (WC) with cardiometabolic risk (CMR). Objective This study assessed whether NAFLD modifies associations between BMI and WC with 5‐year changes in CMR in 2366 CARDIA study participants. Methods Non‐contrast CT was used to quantify liver attenuation, with ≤51 Hounsfield Units (HU) used to define NAFLD in the absence of secondary causes of excess liver fat. The dependent variable was the average Z score of fasting glucose, insulin, triglycerides [log], (−) high‐density lipoprotein cholesterol (HDL‐C), and systolic blood pressure(SBP). Multivariable linear regression was used to estimate the associations between BMI and WC with CMR. Effect modification by NAFLD was assessed by an interaction term between NAFLD and BMI or WC. Results The final sample had 539 (23%) NAFLD cases. NAFLD modified the association of BMI and WC with CMR (interaction p < 0.0001 for both). BMI and WC were associated with CMR in participants without NAFLD ( p < 0.001), but not among those with NAFLD. Participants with NAFLD and normal BMI and WC had CMR estimates that were higher than those without NAFLD in the obese categories. Among those without NAFLD the 5 years CMR change estimate was 0.09 (95% CI: 0.062, 0.125) for BMI ≥30 kg/m 2 compared to −0.06 (−0.092, −0.018) for BMI < 25 kg/m 2 , and among those with NAFLD, these estimates were 0.15 (0.108, 0.193) and 0.16 (−0.035, 0.363). Conclusions NAFLD modifies associations of BMI and WC with CMR. Compared with BMI and WC, NAFLD was more strongly associated with CMR. In the presence of NAFLD, BMI and WC were not associated with CMR. These findings have implications for clinical screening guidelines.
The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder
Cameron, Anne P., Chung, Doreen E. , Dielubanza, Elodi , Enemchukwu, Ekene , Ginsberg, David A. , Linder, Brian J. , Rovner, Eric S., Souter, Lesley , Welk, Blayne , Cameron, Anne P. , Linder, Brian J , Helfand, Brian T. , Reynolds, William M. , Suskind, Anne M. , Takacs, Elizabeth B. , Smith, Ariana L.

Mayo Clinic

Journal of Urology | April 23, 2024 | Volume: 212 | Issue: 1 | Pages: 11-20

10.1097/ju.0000000000003985 | PMID 38651651 Get It

Brugada Syndrome in a Transplanted Heart: Implications for Organ Transplant Screening Process
Fatunde, Olubadewa A. , Maleszewski, Joseph J. , Murray, David R. , Shen, Win‐Kuang , Pereira, Naveen L. , Rattanawong, Pattara , Maleszewski, Joseph J , Shen, Win-Kuang , Pereira, Naveen L , Fatunde, Olubadewa A , Rattanawong, Pattara

Mayo Clinic

Circulation: Genomic and Precision Medicine | April 23, 2024 | Volume: 17 | Issue: 3 | Pages: No page available

10.1161/circgen.123.004533 | PMID 38651350 Get It

ARISE I Consensus Statement on the Management of Chronic Subdural Hematoma
Kan, Peter , Fiorella, David , Dabus, Guilherme , Samaniego, Edgar A. , Lanzino, Giuseppe , Siddiqui, Adnan H. , Chen, Huanwen , Khalessi, Alexander A. , Fifi, Johanna T , Bain, Mark, Wakhloo, Ajay K. , Roundtable, on behalf of the ARISE I Academic Industry, Fifi, Johanna T , Colby, Geoffrey P , Wakhloo, Ajay K , Fiorella, David , Siddiqui, Adnan H , Samaniego, Edgar A , Lanzino, Giuseppe , Dabus, Guilherme C. , Mendes Pereira, Vitor , Colby, Geoffrey P. , Arthur, Adam Stephen , Roundtable, on behalf of the ARISE I Academic Industry, Chen, Huanwen

Mayo Clinic

Stroke | April 22, 2024 | Volume: 55 | Issue: 5 | Pages: 1438-1448

10.1161/strokeaha.123.044129 | PMID 38648281 Get It

ARISE (Aneurysm/AVM/cSDH Roundtable Discussion With Industry and Stroke Experts) organized a one-and-a-half day meeting and workshop and brought together representatives from academia, industry, and government to discuss the most promising approaches to improve outcomes for patients with chronic subdural hematoma (cSDH). The emerging role of middle meningeal artery embolization in clinical practice and the design of current and potential future trials were the primary focuses of discussion. Existing evidence for imaging, indications, agents, and techniques was reviewed, and areas of priority for study and key questions surrounding the development of new and existing treatments for cSDH were identified. Multiple randomized, controlled trials have met their primary efficacy end points, providing high-level evidence that middle meningeal artery embolization is a potent adjunctive therapy to the standard (surgical and nonsurgical) management of neurologically stable cSDH patients in terms of reducing rates of disease recurrence. Pooled data analyses following the formal conclusion and publication of these trials will form a robust foundation upon which guidelines can be strengthened for cSDH treatment modalities and optimal patient selection, as well as delineate future lines of investigation.
The paraneurium and the tumefactive appearance of peripheral nerve neurolymphomatosis: illustrative case
Kendziora, Ryan W., Wismayer, David J. Schembri, Spinner, Robert J. , Schembri Wismayer, David J, Barone, Damiano G. , Broski, Stephen M.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | April 22, 2024 | Volume: 7 | Issue: 17 | Pages: No page available

10.3171/case24125 | PMID 38648674 Get It

BACKGROUND Peripheral neurolymphomatosis (NL) is an often-misdiagnosed condition characterized by lymphomatous infiltration within the peripheral nerves. Its rarity and complexity frequently result in delayed diagnosis and suboptimal patient outcomes. This study aims to elucidate the role of the paraneurium (circumneurium) in NL, emphasizing its diagnostic and therapeutic significance. OBSERVATIONS A 72-year-old man presented with lesions on his right lower eyelid. Initial diagnostics were inconclusive until an excisional biopsy confirmed extranodal marginal zone lymphoma. Following a complete metabolic response to rituximab treatment, the patient relapsed 14 months later with progressive lymphoma and bilateral sciatic nerve involvement, as confirmed by positron emission tomography–computed tomography and magnetic resonance imaging. LESSONS This paper underscores the critical role of the paraneurium in NL, enhancing understanding of its pathophysiology. Integrating advanced imaging techniques have proved essential in accurately identifying neurolymphomatous involvement within the paraneurium. This study paves the way for more effective management strategies in NL and similar conditions, focusing on improving patient care and outcomes.
Editorial: Foretelling the future—Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease
Bruining, David H. , Urquhart, Siri A. , Fletcher, Joel G.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 21, 2024 | Volume: 59 | Issue: 11 | Pages: 1455-1456

10.1111/apt.17991 | PMID 38643503 Get It

LINKED CONTENTThis article is linked to Fernandez‐Clotet et al paper. To view this article, visithttps://doi.org/10.1111/apt.17968
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
DiNardo, Courtney D. , Roboz, Gail J. , Watts, Justin M. , Madanat, Yazan F. , Prince, Gabrielle T., Baratam, Praneeth , Botton, Stéphane de , Stein, Anthony S. , Foran, James M. , Arellano, Martha , Sallman, David A. , Marchione, Dylan M. , Patel, Prapti A. , Kapsalis, Stephanie M., Garcia‐Manero, Guillermo , Fathi, Amir T. , de Botton, Stéphane , Fathi, Amir T , DiNardo, Courtney , Roboz, Gail J , Madanat, Yazan , Hossain, Mohammad Sharif , Bai, Xiaofei

Mayo Clinic

Blood Advances | April 19, 2024 | Volume: 8 | Issue: 15 | Pages: 4209-4220

10.1182/bloodadvances.2023012302 | PMID 38640348 Get It

Abstract Ivosidenib is a first-in-class mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor with efficacy and tolerability in patients with advanced mIDH1 hematologic malignancies, leading to approval in frontline and relapsed/refractory (R/R) mIDH1 acute myeloid leukemia. We report final data from a phase 1 single-arm substudy of once-daily ivosidenib in patients with R/R mIDH1 myelodysplastic syndrome (MDS) after failure of standard-of-care therapies. Primary objectives were to determine safety, tolerability, and clinical activity. The primary efficacy end point was the complete remission (CR) + partial remission (PR) rate. Nineteen patients were enrolled; 18 were included in the efficacy analysis. Treatment-related adverse events occurred in 8 (42.1%) patients, including a grade 1 QT interval prolongation in 1 (5.3%) patient and grade 2 differentiation syndrome in 2 (10.5%) patients. Rates of CR + PR and objective response (CR + PR + marrow CR) were 38.9% (95% confidence interval [CI], 17.3-64.3) and 83.3% (95% CI, 58.6-96.4), respectively. Kaplan-Meier estimates showed a 68.6% probability of patients in CR achieving a remission duration of ≥5 years, and a median overall survival of 35.7 months. Of note, 71.4% and 75.0% baseline red blood cell (RBC)- and platelet-transfusion-dependent patients, respectively, became transfusion independent (TI; no transfusion for ≥56 days); 81.8% and 100% of baseline RBC and platelet TI patients, respectively, remained TI. One (5.3%) patient proceeded to a hematopoietic stem cell transplant. In conclusion, ivosidenib is clinically active, with durable remissions and a manageable safety profile observed in these patients. This trial was registered at www.ClinicalTrials.gov as #NCT02074839.
Applying a Health Equity Lens to Intraoperative Opioid Administration and Postoperative Pain
Milam, Adam J. , Youssef, Mohanad R. , Ugochukwu, Kenechukwu, Hanson, Kristine T. , Raynor, Gwendolyn, Milam, Adam J , Hanson, Kristine , Habermann, Elizabeth B. , Brennan, Emily , Porter, Steven B. , Harbell, Monica W. , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | April 19, 2024 | Volume: 139 | Issue: 3 | Pages: 675-678

10.1213/ane.0000000000006968 | PMID 38640079 Get It